RxDoctor Payments Data

Sarah Yagerman, MD

MOHS-Micrographic Surgery · New York, NYNPI 1568873628

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.0% of the total across 305 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,304, 5.1 times the $450 reported in 2019.

$7,510in general payments, 2019–2025

Across 305 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Dermavant Sciences, Inc.$865
  • Regeneron Healthcare Solutions, Inc.$770
  • AbbVie$761
  • Incyte Corporation$627
  • Galderma Laboratories, L.p.$486
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$7,21096%
  • Education$3004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,510 in reported general payments places this provider in the 75th percentile of 75 mohs-micrographic surgery providers in New York.

See all mohs-micrographic surgery providers in New York

Medicare billing

Part B allowed, 2024
$503,883
Medicare patients
613
Services billed
2,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$41,916
Acitretin20$2,827
Clobetasol Propionate44$1,792
Gentamicin Sulfate43$1,458
Ketoconazole78$1,126
Fluorouracil14$1,070
Mupirocin137$962
Tretinoin11$713
Triamcinolone Acetonide59$556
Fluocinolone Acetonide13$552
Doxycycline Monohydrate21$213
Finasteride11$185
ValacyclovirValacyclovir Hcl20$159
Hydrocortisone24$142
Minoxidil13$112

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →